

# Sustainability of mHealth interventions:

## Patients' preferences and willingness to pay user fees for mHealth ART adherence support tool in resource limited settings

Agnes Bwanika N<sup>1</sup>, Sarah M Nabaggala<sup>1</sup>, Dathan Mirembe Byonanebye<sup>1</sup>, Josephine Akirana<sup>1</sup>, Benson Nasasira<sup>1</sup>, Elizabeth Oseku<sup>1</sup>, Noela C Owarwo<sup>1</sup>, Agnes Kiragga<sup>1</sup>,

Barbara Castelnuovo<sup>1</sup>, Andrew Kambugu<sup>1</sup>, Rachel King<sup>3</sup>, Elly Katabira<sup>1,4,</sup>Mohammed Lamorde<sup>1</sup>, Rosalind Parkes-Ratanshi <sup>1,2</sup>

<sup>1</sup>Ugandan Academy for Health Innovation and Impact, Infectious Disease Institute, Makarere University Kampala, Uganda, <sup>2</sup> Institute of Public Health, University of Cambridge, UK, <sup>3</sup> University of California, San Francisco, <sup>4</sup> College of Health Sciences, School of Medicine, Makerere University, P.O.Box 7062, Kampala, Uganda

Correspondence: anaggirinya@idi.co.ug Phone: +256752521570, +256-31-2307000 Fax: +256-314307290



**POSTER: TUPED 683** 

Background: The increasing mobile phone penetration in Africa offers unique opportunities for leveraging mobile health (mHealth) interventions to enhance health care<sup>1</sup>. Although there is suggestive evidence for benefit of mHealth for HIV care on ART adherence<sup>2,3,4,5</sup> and retention in care<sup>6,7,8</sup>, there are concerns about the scalability and sustainability of these interventions. Within a randomized controlled trial, we assessed participants' willingness to pay a fee for Call for life Uganda (C4LU), a software that helps in ART adherence, appointment reminders and health tips with people living with HIV/AIDS via mobile phones.

Methodology: randomised (1:1 ratio) at an urban (Infectious Diseases Institute Clinic) and peri-urban HIV clinic (Kasangati HC) to either Standard of Care (SoC)- face-to-face counsellor adherence support or SoC plus the C4LU mHealth tool. C4LU uses Interactive Voice Response or text messages delivered via MoTech-based Connect for Life<sup>TM</sup> (Janssen, Global Public Health-J&J). The C4LU offers:

- Daily pill reminders
- Appointment visit reminders
- Symptom reporting and management
- Weekly health Info-tips


determine willingness to pay, participants interviewed about their desire to continue with adherence support and willingness to pay a nominal fee for C4LU at the end of the study.

We determined the proportion of patients willing to pay (±95% confidence interval), stratified by study arm. We determined the predictors of willingness to pay using multivariate logistic regression.


Results: Overall, majority of the participants were female, young and educated (Table 1)

## Table 1:Characteristics of study participants

|  | Standard of Care arm N= 245(%) | Interventional arm N=258(%) | Total N=503   |
|--|--------------------------------|-----------------------------|---------------|
| Study Site                               |                                |                             |               |
| Infectious Diseases Institute-<br>Mulago | 137(53.1%)                     | 136(55.5%)                  | 273( 54.3%)   |
| Kasangati Health Centre IV               | 121(46.9%)                     | 109(44.5%)                  | 230(45.7%)    |
| Gender                                   |                                |                             |               |
| Female                                   | 173(67.1%)                     | 164(66.9%)                  | 337(67.0%)    |
| Male                                     | 85(32.9%)                      | 81(33.1%)                   | 166(33.0%)    |
| Age( yrs)                                |                                |                             |               |
| 16-24                                    | 62(25.3%)                      | 62(24.0%)                   | 124(24.7%)    |
| 25-35                                    | 101(39.2%)                     | 83(33.8)                    | 184(36.6%)    |
| 36-50                                    | 77(29.8%)                      | 83(33.8%)                   | 160(31.8%)    |
| 51+                                      | 18(6.98%)                      | 17(6.9%)                    | 35(7.0%)      |
| Currently having a partner/spo           | use                            |                             |               |
| Yes                                      | 199(77.1%)                     | 185(75.5%)                  | 384(76.3%)    |
| No                                       | 59(22.9%)                      | 60(24.5%)                   | 119(23.7%)    |
| Highest education Level                  |                                |                             |               |
| None                                     | 12(4.7%)                       | 7(2.9%)                     | 19( 3.8%)     |
| Primary                                  | 96(37.21%)                     | 95(38.8%)                   | 191(38.0%)    |
| Secondary                                | 109(42.3%)                     | 111(45.3%)                  | 220(43.7%)    |
| Tertiary                                 | 41(15.9%)                      | 32(13.1%)                   | 73(14.5%)     |
| Employment status                        |                                |                             |               |
| Yes                                      | 181(70.2%)                     | 170(69.4%)                  | 351(69.8%)    |
| No                                       | 77(29.8%)                      | 75(30.6%)                   | 152(30.2%)    |
| ART duration yrs: Median (IQR)           | 2.7(0.5-5.2)                   | 3(0.5-5.2)                  | 2.9( 0.5-5.4) |



Rana et al..2016



**Acknowledgements:** We would like to thank the patients and staff of the IDI and Kasangati Clinics. This study and the Ugandan Academy are funded by Janssen, the Pharmaceutical Companies of Johnson & Johnson as part of its

commitment to global public health through collaboration with the Johnson & Johnson Corporate Citizenship Trust

References: S. Akter, P. Ray, et al 2010, Garofalo et al, May 2016, Lester et al., 2010, A. R.

Campbell et al., 2018;<sup>5</sup>J. I. Campbell & Haberer, 2015, <sup>6</sup> Kiwanuka et al., 2018, <sup>7</sup>Smillie et al.,2014, <sup>8</sup>

janssen Johnson Johnson CORPORATE **CITIZENSHIP** TRUST

C4LU after study completion

Figure 3: Participants' Willingness to continue using






Figure 4: Willingness to pay for C4LU across study arms



- Overall, 95% were willing to continue using C4LU with 77.8% willing to pay for the service.
- In the C4LU intervention arm, 240 (97.96%) wanted continued adherence support and 168/240 (70.00%) were willing to pay for the service.
- Within the SoC arm, 238 (92.22%) wanted continued adherence support, and 157(65.97%) were willing to pay for C4LU.
- Persons receiving care at the peri-urban clinic (OR 3.12, 95% CI 1.43-9.11.86) and those in the C4LU arm (OR 4.2, 95% CI 1.55-11.84) were more willing to continue and pay for the service.
- Males were more likely to continue with and pay for adherence support although this was not statistically significant. There was no association seen with age.



## Conclusion:

- With this high overall willingness to continue using and pay for C4LU services, UA, is preparing for scale up studies in young people with HIV in Mid-Western region and in HIV-TB co-infected patients in the central region.
- mHealth tools being evaluated today, fall short of defined studies and projects, and the best way to have a country sustainable model would be a co-pay model that empowers PLHIV and caregivers in resource limited settings.